L23.11 Kilder
Etelkalsetid
Legemidler mot overvekt/fedme
Tak, Y.J., Lee, S.Y. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?. Curr Obes Rep 10, 14–30 (2021). https://doi.org/10.1007/s13679-020-00422-w
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004 Jan;27(1):155-61. doi: 10.2337/diacare.27.1.155. Erratum in: Diabetes Care. 2004 Mar;27(3):856. PMID: 14693982.
Dahlberg S, Chang ET, Weiss SR, Dopart P, Gould E, Ritchey ME. Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review. Diabetes Metab Syndr Obes. 2022 Sep 29;15:3049-3067. doi: 10.2147/DMSO.S381652. PMID: 36200062; PMCID: PMC9529009.
Hjelmesæth JS, Lund RS, Sagen JV, Valderhaug TG. Vektreduserende medisiner – for hvem, hvordan, hvor lenge? Tidsskr Nor Legeforen 2022 doi: 10.4045/tidsskr.22.0115.
Rolin J, Ødegård RA, Amundsen VV, Köpp UMS, Kokkvoll A, Júlíusson RB, Hjelmesæth JS. Medikamentell tilleggsbehandling for vektreduksjon hos ungdom med alvorlig fedme Tidsskr Nor Legeforen 2022 doi: 10.4045/tidsskr.22.0540.